News & Articles

Detecting lung cancer early with advanced flow cytometry

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung

SAN ANTONIO, TX – (June 3, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of “The Drive for Early Detection,” a case study detailing how bioAffinity Technologies utilizes support from Cardinal Health™ OptiFreight® Logistics to help meet demand for CyPath® Lung, a noninvasive test for detection of early stage lung cancer. “Our innovative, accurate diagnostic for lung cancer relies on dependable, on-time delivery of viable sputum samples to our laboratory for processing and providing reliable results to patients and their physicians,” bioAffinity President and CEO Maria Zannes said. “CyPath® Lung has a strategic logistics partner in OptiFreight® Logistics who works with us to solve challenges, reduce...
Read More

bioAffinity Technologies Reports First Quarter 2025 Results

CyPath® Lung sales up 276% year-over-year SAN ANTONIO, Texas (May 15, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of...
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology laboratory Services

Learn More about

The CyPath® Lung Flow Cytometry Test is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company,  as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ

Subscribe for News from bioAffinity Technologies